Anti-Human DNAM-1-Biotin

Purified Recombinant Human DNAM-1 (>98%)

This biotinylated antigen affinity purified polyclonal antibody has been 0.2 µm filtered and lyophilized from modified Dulbecco’s phosphate buffered saline (1X PBS) pH 7.2 – 7.3 containing 50 µg of bovine serum albumin per µg of antibody with no calcium, magnesium, or preservatives present.

Lyophilized

The lyophilized, biotinylated antigen affinity purified polyclonal antibody can be stored desiccated at -20°C to -70°C for up to twelve months from date of receipt. The reconstituted bioin conjugate can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted conjugate, aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. No detectable loss of activity was observed after six months.

Next Day Ambient

Goat Anti-Human DNAX Accessory Molecule 1 (DNAM-1) recognizes Human DNAM-1. This antigen affinity purified polyclonal antibody was purified using a proprietary chromatographic technique that includes covalently immobilizing the antigen proteins or peptides to agarose based beads. This purification method enhances specificity, reduces nonspecific binding of extraneous IgG and provides you with the most reliable reagent available for your early discovery research.

DNAX accessory molecule 1 (DNAM-1), is a tyrosine-phosphorylated signal-transducing molecule belonging to the immunoglobulin superfamily and participates in primary adhesion during cytotoxic T lymphocyte-mediated cytotoxicity. <sup<1
DNAM-1 is a functional glycoprotein expressed on immune cells, such as natural killer and T-cells. It is activated upon interaction with its biological ligands, the poliovirus receptor and nectin-2. Signaling cascades involving stimulation of DNAM-1 lead to various biological responses, including target cell lysis and immune cell activation. DNAM-1 appears to be an integral molecule in immune responses in cancer, allergic inflammatory disorders and autoimmune diseases.²

1. Phillips, JH. et al.(1996) Immunity. 4(6):573-81.
2. Levi-Schaffer, F. et al. (2008) Curr Opin Investig Drugs. 9(5):491-6.